A 2-hour-old preterm neonate (32 weeks) born to a mother with prolonged rupture of membranes presents with severe respiratory distress (RR 70/min, grunting, intercostal retractions, APGAR 5 at 1 minute). Chest X-ray shows ground-glass appearance consistent with respiratory distress syndrome. What is the drug of choice for immediate treatment?

Question

Accepted Answer

A. Poractant alfa (pulmonary surfactant). ## Respiratory Distress Syndrome (RDS) in Preterm Neonates: Surfactant Therapy ### Clinical Context This preterm neonate (32 weeks) with RDS (ground-glass infiltrates on CXR, severe respiratory distress) requires immediate surfactant replacement. RDS is caused by surfactant deficiency in immature lungs, leading to increased surface tension, alveolar collapse, and ventilation-perfusion mismatch. ### Drug of Choice: Poractant Alfa (Pulmonary Surfactant) **Key Point:** Exogenous surfactant (poractant alfa, beractant, calfactant) is the gold standard first-line therapy for RDS in preterm neonates. It must be administered within the first few hours of life for maximum efficacy. **High-Yield:** Surfactant therapy reduces mortality by ~40% and incidence of pneumothorax and pulmonary interstitial emphysema (PIE) by ~50% in preterm infants with RDS. ### Surfactant Preparations Available | Preparation | Type | Dose | Route | Notes | | --- | --- | --- | --- | --- | | **Poractant alfa** | Natural (porcine) | 2.5 mg/kg initially, then 1.25 mg/kg at 12 & 24 hrs | Intratracheal | Most potent; preferred first-line | | Beractant | Natural (bovine) | 4 mg/kg as single dose, repeat × 3 | Intratracheal | Requires multiple doses | | Calfactant | Natural (calf) | 3 mg/kg, repeat × 2 | Intratracheal | Rapid onset | | Lucinactant | Synthetic | 5.8 mg/kg | Intratracheal | Less effective than natural surfactants | **Clinical Pearl:** Poractant alfa is the most potent surfactant preparation and requires the lowest total dose (2.5 mg/kg initially vs. 4 mg/kg for beractant), making it the preferred choice in many centers. It is administered intratracheally via an endotracheal tube. ### Mechanism of Action 1. Reduces surface tension at air-liquid interface in alveoli 2. Increases lung compliance and functional residual capacity (FRC) 3. Prevents alveolar collapse during expiration 4. Improves oxygenation and ventilation within minutes ### Timing & Administration - **Timing:** Within 1–2 hours of birth (earlier = better outcomes) - **Route:** Intratracheal (via endotracheal tube) - **Ventilation:** Continue mechanical ventilation; may need to reduce ventilator settings as compliance improves - **Repeat dosing:** Based on clinical response and residual respiratory distress **Warning:** Do NOT confuse surfactant with methylxanthines or doxapram — these are respiratory stimulants used for apnea of prematurity, NOT for RDS. Surfactant is a replacement therapy; methylxanthines are adjunctive. ### Comparison: RDS Medications vs. Apnea of Prematurity Medications | Condition | Drug | Mechanism | Indication | | --- | --- | --- | --- | | **RDS (surfactant deficiency)** | **Poractant alfa** | Replaces deficient surfactant | Acute RDS in preterm infants | | Apnea of prematurity | Caffeine citrate | CNS respiratory stimulant | Recurrent apneic episodes | | Apnea of prematurity | Theophylline | Methylxanthine (less used now) | Apnea prophylaxis | | Apnea of prematurity | Doxapram | Respiratory stimulant | Severe apnea refractory to caffeine | **High-Yield Mnemonic:** **RESCUE** for surfactant indications in RDS: - **R**espiratory distress (clinical signs: grunting, retractions, tachypnea) - **E**arly administration (within 2 hours of birth) - **S**evere hypoxemia (PaO~2~ <60 mmHg on supplemental O~2~) - **C**hest X-ray findings (ground-glass, air bronchograms) - **U**se intratracheal route - **E**xogenous surfactant (poractant alfa preferred) ### Antenatal Corticosteroids: Synergistic Benefit **Clinical Pearl:** Maternal antenatal corticosteroids (betamethasone, dexamethasone) given 24 hours to 7 days before preterm delivery significantly enhance endogenous surfactant production and further reduce RDS severity. This neonate should have received antenatal steroids if delivery was anticipated. ### Algorithm: RDS Management ```mermaid flowchart TD A[Preterm neonate
with respiratory distress]:::outcome --> B{Clinical signs + CXR
consistent with RDS?}:::decision B -->|Yes| C[Intubate and ventilate]:::action C --> D[Administer surfactant
Poractant alfa 2.5 mg/kg IT]:::action D --> E[Monitor response
Improve oxygenation?]:::decision E -->|Yes| F[Wean ventilator settings]:::action E -->|No| G[Repeat surfactant dose
at 12 & 24 hrs]:::action F --> H[Supportive care
Fluid, nutrition, monitoring]:::action G --> I[Reassess clinical status]:::action I --> J[Recovery or complications?]:::decision J -->|Uncomplicated| K[Gradual weaning]:::action J -->|Complications| L[Manage BPD, IVH, NEC]:::action ``` [cite:Textbook of Neonatal Resuscitation 8e, American Academy of Pediatrics; Harrison 21e Ch 173]

Answer

B. Doxapram

Answer

C. Caffeine citrate

Answer

D. Methylxanthine (theophylline)

Explanation

Respiratory Distress Syndrome (RDS) in Preterm Neonates: Surfactant Therapy

Clinical Context

Drug of Choice: Poractant Alfa (Pulmonary Surfactant)

Surfactant Preparations Available

Mechanism of Action

Timing & Administration

Comparison: RDS Medications vs. Apnea of Prematurity Medications

Antenatal Corticosteroids: Synergistic Benefit

Algorithm: RDS Management

Practice similar questions

Join our NEET PG community

Preparation	Type	Dose	Route	Notes
Poractant alfa	Natural (porcine)	2.5 mg/kg initially, then 1.25 mg/kg at 12 & 24 hrs	Intratracheal	Most potent; preferred first-line
Beractant	Natural (bovine)	4 mg/kg as single dose, repeat × 3	Intratracheal	Requires multiple doses
Calfactant	Natural (calf)	3 mg/kg, repeat × 2	Intratracheal	Rapid onset
Lucinactant	Synthetic	5.8 mg/kg	Intratracheal	Less effective than natural surfactants

Condition	Drug	Mechanism	Indication
RDS (surfactant deficiency)	Poractant alfa	Replaces deficient surfactant	Acute RDS in preterm infants
Apnea of prematurity	Caffeine citrate	CNS respiratory stimulant	Recurrent apneic episodes
Apnea of prematurity	Theophylline	Methylxanthine (less used now)	Apnea prophylaxis
Apnea of prematurity	Doxapram	Respiratory stimulant	Severe apnea refractory to caffeine